DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Robson ME, Tung N, Conte P. et al.
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianʼs choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Ann Oncol 2019;
30: 558-566
We do not assume any responsibility for the contents of the web pages of other providers.